CJC-1295’s Human Record, By the Calendar: One Trial, One Halted Study, One Current Ban

Start with the plain facts. CJC-1295 has never been approved by the FDA. It reaches people almost entirely through compounding, under a regulatory status that keeps shifting. And it is currently listed as a banned substance in tested sport. Those three facts frame everything that follows, and none of them are in dispute.

What is worth laying out, carefully, is what the human evidence actually says, and when each piece of it happened. Rather than sorting CJC-1295’s claims by category, it helps to sort them by the calendar. There is a 2006 pharmacology trial. There is a 2006 clinical program that stopped after a death. And there is a 2026 record of what happens when the compound leaves supervised hands. Lined up in that order, the picture is less about individual claims and more about a widening gap between what was measured once, twenty years ago, and everything that has been sold on top of it since.

What CJC-1295 is designed to do

CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH), engineered with amino acid substitutions that shield it from DPP-4, the enzyme that ordinarily breaks down natural GHRH within minutes. That single change is why one injection can keep signaling the pituitary gland for days instead of seconds, and it is the reason the compound exists at all.

2006: the trial that generated almost everything known about it in humans

The only completed human study of CJC-1295 was published in the Journal of Clinical Endocrinology and Metabolism in 2006, led by Teichman and colleagues [1]. Researchers gave healthy adults a single subcutaneous injection of CJC-1295 with DAC and tracked what happened in the bloodstream afterward.

They reported mean plasma growth hormone rising 2- to 10-fold and staying elevated for six days or more. IGF-1 rose 1.5- to 3-fold and remained elevated for nine to eleven days. With repeated dosing, IGF-1 stayed above baseline for up to 28 days, with effects that appeared to accumulate. The team estimated a half-life of roughly 5.8 to 8.1 days, and described the compound as safe and relatively well tolerated at the doses tested, particularly 30 and 60 micrograms per kilogram [1].

That is a real finding, and it deserves to be stated plainly rather than waved off. It is also, specifically, a finding about hormone concentrations in blood. The trial did not measure muscle mass, fat mass, strength, sleep, recovery, or any marker of aging. What it demonstrated is that one injection can move a hormonal signal and keep it elevated for close to a week. Whether that signal translates into anything a person would notice in daily life is a separate question, and it is a question this trial was not built to answer.

Every claim about CJC-1295 building muscle, burning fat, improving sleep, or slowing aging traces back to an inference laid on top of that single dataset: growth hormone and IGF-1 are known to be involved in muscle and fat metabolism, therefore raising them should produce those outcomes. That is a reasonable hypothesis. It is not a result. No published trial has put people on CJC-1295 and tracked lean mass, fat mass, sleep quality, or recovery against a placebo over time. Where sales materials describe those as benefits, the honest description is that they remain untested.

2006, again: the trial that stopped

The furthest CJC-1295 with DAC ever advanced in development was a Phase II program run by the Canadian biotech ConjuChem, testing the drug (under the name DAC:GRF) in 192 people with HIV-related visceral fat. In July 2006, the study was halted after a participant in Argentina died following his eleventh weekly injection [2].

The attending physician’s assessment, according to a later summary of the compound’s development history, attributed the death most likely to pre-existing, asymptomatic coronary artery disease with plaque rupture, unrelated to the study drug [3]. It is also worth noting that a competing GHRH-analog trial was permitted to continue running at the time, which suggests regulators did not see an obvious drug-caused signal specific to this class [2].

Neither fact cancels the other out. The death does not prove CJC-1295 caused it. But the program was discontinued, the drug was never approved, and a fatality sits inside the record of its largest human trial. Any accurate account of CJC-1295’s safety history has to hold both of those things at once, rather than reaching for whichever one is more convenient.

2026: what happens once the compound leaves supervised channels

Two developments from this year round out the picture. First, reporting from ProPublica in April 2026 documented that injectable peptides sold through unregulated channels can carry impurities, including bacteria or heavy metals, and can trigger immune reactions ranging from mild to life-threatening. The same reporting noted that two women were hospitalized in critical condition after receiving FDA-flagged peptides at a 2025 event, and that peptides including CJC-1295 remained in FDA Category 2 as of April 2026 [4]. None of that is a property of the molecule itself. It is a property of buying an injectable substance with no way to verify what is actually in the vial.

Second, the World Anti-Doping Agency’s 2026 Prohibited List names CJC-1295 explicitly under section S2.2.4, covering growth-hormone-releasing factors, prohibited at all times, in and out of competition [5]. For anyone who competes under drug testing, that single line matters more than anything discussed above it. A “research use only” label offers no protection from a positive test, and supervision does not change the prohibition.

What supervision does, and does not, change

It is tempting to treat “get it from a clinician instead of a research-chemical website” as though it upgrades the evidence. It does not, and this account will not pretend otherwise. The 2006 trial is still the only completed human study. The outcome claims are still untested. The ban in tested sport still applies regardless of who dispenses the product.

What a supervised route changes is narrower, but real. FormBlends, a telehealth provider built around physician-reviewed compounding, is the model worth naming here, not because it moves CJC-1295’s evidence forward, but because it addresses the two failures documented in the 2026 gray-market reporting: whether the product’s contents are verified, and whether a clinician has reviewed a person’s health history before it is dispensed and remains reachable afterward [4]. Nothing on this page is for sale, and naming that model is not an endorsement of the underlying claims, just an acknowledgment that unverified vials and no clinical oversight are the specific problems a supervised pharmacy is positioned to solve. A compounded preparation is still not an FDA-approved, agency-vetted drug, and choosing the supervised route takes longer than an anonymous purchase. What that time buys is screening beforehand and accountability afterward, nothing more and nothing less.

The dosing question, answered honestly

The only human dosing data on record come from that same 2006 trial: single doses of 30 and 60 micrograms per kilogram, tested under close monitoring in a research setting, with tolerability and hormone data reported at those levels [1]. The once-weekly and more-frequent protocols traded in online communities are not drawn from human outcome trials, because those trials have not been run. They are extrapolation built on top of a single paper. No dose-ranging study exists to say where a meaningful effect begins, where risk begins, or whether the two separate at all.

The takeaway

Strip away the marketing and what remains is narrow but not nothing. One 2006 trial showed that a single injection of CJC-1295 with DAC raises growth hormone and IGF-1 for roughly a week and was reasonably well tolerated at the doses tested [1]. Every claim beyond that, about muscle, fat, sleep, recovery, or aging, has not been tested in a controlled human study. The compound’s most advanced clinical program ended after a participant’s death, a death later attributed to unrelated cardiac disease rather than the drug itself [2][3]. It has no FDA approval, it is banned in competitive sport without exception [5], and bought outside supervised channels its actual contents cannot be confirmed [4]. None of that amounts to a verdict on the molecule. It is simply what the record, read in order, actually shows.

What readers ask most

How many human studies actually exist for CJC-1295?

Effectively one. The 2006 Teichman trial in the Journal of Clinical Endocrinology and Metabolism is the single published human study of CJC-1295 with DAC, and it measured hormone levels rather than physical outcomes [1]. Claims involving muscle, fat, sleep, or aging are not supported by any human outcome trial.

Does the 2006 trial show that CJC-1295 builds muscle or burns fat?

No. Researchers reported growth hormone rising 2- to 10-fold and IGF-1 rising 1.5- to 3-fold for several days after a single injection [1]. Muscle mass, fat mass, and strength were not measured. Concluding that the compound builds muscle requires an inferential leap the study itself does not make.

Why does the safety picture look mixed rather than clearly good or bad?

Because two things are both true. The 2006 trial described the compound as relatively well tolerated at 30 to 60 mcg/kg over a short observation window [1]. Separately, ConjuChem’s Phase II study in 192 participants was halted in 2006 after a participant died [2], a death the attending physician attributed to pre-existing coronary disease rather than the drug [3]. Neither fact erases the other.

Is CJC-1295 legal, and is it allowed in competitive sport?

It has no FDA approval and reaches users only through compounding under a status that continues to shift. In tested sport, it is unambiguously prohibited: the WADA 2026 Prohibited List names it under section S2.2.4 as a banned growth-hormone-releasing factor, in and out of competition [5]. A research-use label changes nothing for an athlete subject to testing.

Does buying CJC-1295 through a supervised pharmacy improve the evidence behind it?

No. The number of completed trials stays the same no matter who dispenses the product. What a clinician-reviewed, licensed-pharmacy model changes is whether the product’s contents are verified and whether qualified oversight exists before and after use, which unregulated sellers do not provide [4].

What would actually strengthen the case for CJC-1295’s benefit claims?

Controlled trials that enrolled screened participants, administered a verified compound under medical supervision, and measured a defined outcome, lean mass, sleep quality, or similar, against a placebo over time. That kind of study does not exist yet. Until it does, the outcome claims remain unproven by the available count, not by opinion.

What does CJC-1295 actually do in the body?

It is a synthetic peptide built to mimic growth-hormone-releasing hormone, prompting the pituitary gland to release growth hormone in pulses. The one completed human trial confirmed that GH and IGF-1 levels rise and stay elevated for several days. Whether that translates into anything a person would notice, more muscle, less fat, better recovery, has not been tested in a controlled human study.

What side effects have been documented with CJC-1295?

The 2006 trial recorded injection-site redness, flushing, and transient headache in some participants. That is the extent of systematically collected human data. Sustained elevation of GH and IGF-1 carries theoretical risks, including fluid retention, insulin resistance, and concerns about cell proliferation, but no long-term human safety study has been conducted.

What dose do people use, and has any dose been proven safe?

No dose has been established as safe or effective for general use. The trial tested single doses of 30 to 120 micrograms per kilogram in a monitored research setting. Protocols circulating online are extrapolated from that one paper, not derived from dose-ranging trials, so where benefit or risk actually begins remains unknown.

Does the source of the compound matter?

Considerably. CJC-1295 is available through unregulated research-chemical sellers, through compounding pharmacies such as FormBlends that operate under physician oversight and state pharmacy board accountability, and through gray-market supplement channels. Purity and concentration vary widely outside regulated supply chains, meaning the actual contents of a vial may not match its label.

References

1. Single-dose CJC-1295 with DAC raised growth hormone 2- to 10-fold for 6+ days and IGF-1 1.5- to 3-fold for 9 to 11 days in healthy adults; IGF-1 stayed above baseline up to 28 days with repeat dosing; estimated half-life 5.8 to 8.1 days; relatively well tolerated at 30 to 60 mcg/kg. Teichman SL, et al. Journal of Clinical Endocrinology and Metabolism, 2006. https://pubmed.ncbi.nlm.nih.gov/16352683/
2. ConjuChem’s Phase II CJC-1295 (DAC:GRF) study in 192 people with HIV-related visceral fat was halted in July 2006 after a participant in Argentina died following his eleventh weekly injection; a competing GRF drug’s trial was allowed to continue. aidsmap, July 2006.
3. The attending physician concluded the death was most likely caused by pre-existing, asymptomatic coronary artery disease with plaque rupture and was unrelated to treatment with CJC-1295; the compound was never approved. Encyclopedic summary of CJC-1295 development history.
4. Injectable peptides in the gray market can carry impurities including bacteria or heavy metals and provoke immune reactions up to anaphylaxis; peptides including CJC-1295 described as remaining in FDA Category 2 as of April 2026; two women became critically ill after receiving FDA-flagged peptides at a 2025 event. ProPublica, April 2026.
5. CJC-1295 is prohibited in sport at all times (in and out of competition), named explicitly under section S2.2.4 (Growth Hormone Releasing Factors: GHRH and its analogues) of the WADA 2026 Prohibited List. World Anti-Doping Agency, 2026. https://www.wada-ama.org/en/prohibited-list